Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 8, 2020

Medtronic receives clearance for insertable cardiac monitor

Medtronic has received clearance for its LINQ II insertable cardiac monitor (ICM) from the Food and Drug Administration (FDA) in the US, as well as CE Mark in Europe.

Medtronic has received clearance for its LINQ II insertable cardiac monitor (ICM) from the Food and Drug Administration (FDA) in the US, as well as CE Mark in Europe.

LINQ II is a small, wireless ICM for patients with abnormal heart rhythms. These patients require long-term monitoring or continuous management as they experience dizziness, palpitations, syncope (fainting) and chest pain.

The system simplifies diagnosis and monitoring of the patients by providing enhanced accuracy to correctly detect abnormal heart rhythms.

It also eliminates the need for patients to return to the hospital by enabling clinicians to optimise its settings. It is designed to deliver improved device longevity compared to other ICMs.

Medtronic’s Cardiac and Vascular Group cardiac rhythm and heart failure division chief medical officer Rob Kowal said: “In the current Covid-19 environment, the LINQ II system offers patients a seamless way to experience ongoing connectivity between their device and their physician while reducing the need for in-office visits.

“LINQ II gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation (AF) or other abnormal heart rhythms.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Medtronic is planning to launch the LINQ IIICM in the US and Europe later this year.

Meanwhile, the company has made an offer for smaller medical device maker Intersect.

California-based Intersect specialises in drug-delivery tools for ear, nose and throat clinicians, treating chronic sinusitis.

According to a report by Bloomberg, Intersect’s board of directors is currently reviewing the offer with its advisers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU